Close this search box.

New board, staff appointments at BIA

ARTICLE | Management Tracks

Plus: C-Path promotes Romero to CEO, and more from BioPorto and Sanofi

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

January 10, 2024 10:40 PM UTC

As the U.K.’s Bioindustry Association announced that it has crossed the 600-member threshold for the first time, the organization revealed new board and staff appointments. The BIA appointed to its board Ros Deegan, CEO of OMass Therapeutics Ltd.; Shaun Grady, SVP business development operations at AstraZeneca plc (LSE:AZN; NASDAQ:AZN); and Laura Lane, VP of the Lilly Ventures arm of Eli Lilly and Co. (NYSE:LLY). All were elected to three-year terms. The board’s chair is Daniel Mahony, who joined Novo Holdings as senior partner last week.

The BIA promoted Jane Wall to managing director from director of business development and membership services, and noted that CEO Steve Bates would take a more external focus, having completed his tenure as entrepreneurin-residence at Oxford University…